Clinical DevelopmentAN4005 is being investigated in an ongoing Phase 1, multi-center, open-label clinical trial study in patients with advanced solid tumors.
CompetitionThere are several oral small molecules PD-L1 candidates in early development stages, leaving the playing field open for AN4005 to advance.
Pipeline ChallengesThe broad, oncology-focused company portfolio is bolstered by strong external support through close collaborations with global partners.